MLYS
Mineralys Therapeutics, Inc.
NASDAQ · USHealthcareBiotechnology
$26.71-1.40%
Price as of Jul 20, 2026
MLYS financials
Mineralys Therapeutics, Inc. financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating expenses | $170.6M | $192.4M | $84.7M | $31.5M |
| Operating income | -$170.6M | -$192.4M | -$84.7M | -$31.5M |
| Net income | -$154.7M | -$177.8M | -$71.9M | -$29.8M |
| EBITDA | -$154.6M | -$177.8M | -$71.9M | -$28.1M |
| Basic EPS | $-2.29 | $-3.66 | $-1.99 | $-5.77 |
| Diluted EPS | $-2.29 | $-3.66 | $-1.99 | $-5.77 |
| Balance sheet | ||||
| Cash & equivalents | $172.9M | $114.1M | $49.3M | $87.7M |
| Total assets | $661.8M | $205.9M | $251.6M | $114.4M |
| Total liabilities | $15.1M | $14.6M | $10.5M | $166.7M |
| Stockholders’ equity | $646.7M | $191.3M | $241.2M | -$52.3M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 |
| Net debt | -$172.9M | -$114.1M | -$49.3M | -$87.7M |
| Cash flow | ||||
| Operating cash flow | -$142.4M | -$166.3M | -$81.2M | -$29.2M |
| Capital expenditure | -$15.0K | -$96.0K | $0.00 | $0.00 |
| Free cash flow | -$142.4M | -$166.4M | -$81.2M | -$29.2M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | $0.00 | $0.00 | $0.00 | -$1.6M |